drug

Olaparib approved for 800 prostate and breast cancer patients in England

Posted in Medicine on 20th May, 2023
by Alex Muller

When used after surgery and chemotherapy, the drug can also reduce the risk of BRCA-mutant, HER2-negative early breast cancer returning or getting bigger.

Institute of Cancer Research embraces olaparib recommendation

Posted in Medicine on 11th Apr, 2023
by Alex Muller

"Olaparib is an important example of how understanding the underlying genetics of patients, and their tumours’ genomics, can be used to design highly targeted precision medicines.”

NHS approves 'life changing' drug for breast and prostate cancer patients

Posted in Medicine, Science on 6th Apr, 2023
by Alex Muller

Clinical trials have shown that olaparib, also known as Lynparza and manufactured by pharmaceutical firm AstraZeneca, can extend advanced prostate cancer patients’ lives by "an average of six months", NHS England said.

Research Reveals Why Cancers Stop Responding to Kinase-Blocking Drugs and Come Back Stronger

Posted in Medicine on 15th Feb, 2023
by Alex Muller

Study finds that “gatekeeper” mutations make enzymes called kinases more active by destabilizing them in their inactive form, which may explain more aggressive cancer recurrence.

 Improving brain tumour treatment

Posted in Medicine, Science on 14th Feb, 2023
by Alex Muller

Temozolomide, a chemotherapy drug discovered and developed by CRUK scientists, changed brain tumour treatment forever.